Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Blueprint Medicines exceeds revenue expectations, eyes growth opportunities in 2023

Blueprint Medicines delivered strong financial results and outlined growth strategies for 2023, driven by AYVAKIT's performance.
The company faces uncertainties around label negotiation but benefits from strong market access and proactive market expansion efforts.
Opportunities lie in upcoming data presentations, CDK2 program updates, and capturing additional market share in the ISM segment.

Blueprint Medicines reports strong Q1 performance and growth opportunities

Blueprint Medicines showcased strong financial performance, a robust growth strategy, and promising pipeline advancements during the Q1 earnings call. While facing challenges in managing expenses and differentiating sales, the company is well-positioned to capitalize on opportunities in driving AYVAKYT sales and educating providers on SM treatment urgency.

Blueprint Medicines reports strong Q2 results and eyes market expansion

Blueprint Medicines demonstrated solid financial performance and positive market reception for AYVAKIT and BLU-222.
While facing challenges in operational execution and market competition, the company has opportunities for growth through portfolio expansion and market diversification.
Overall, Blueprint Medicines is well-positioned to capitalize on the success of AYVAKIT and the potential of BLU-222 in driving future growth and innovation.

Blueprint Medicines excels in Q3, eyes sustainable growth in 2024

Blueprint Medicines delivered strong Q3 results with a focus on sustainable revenue growth and pipeline advancement.
The company's strengths lie in AYVAKIT's market adoption, high patient retention rates, and promising pipeline assets.
Challenges include managing operating expenses, decreasing cash burn, and expanding market penetration for AYVAKIT.
Opportunities exist in developing new assets, presenting upcoming data, and achieving significant growth in 2024.

Blueprint Medicines reports robust 2023 performance and targets $2B peak sales

Blueprint Medicines' strong 2023 performance with AYVAKIT driving revenue growth sets the stage for continued success in 2024, aiming for peak sales exceeding $2 billion.
Strategic focus on expanding market presence, advancing pipeline assets, and maintaining financial discipline positions the company for sustained growth and profitability.
Opportunities lie in maximizing AYVAKIT's market potential, leveraging BLU-808 in inflammatory disorders, and exploring strategic growth avenues in cancer treatment.

Blueprint Medicines reports robust Q1 earnings, eyes strategic partnerships

Blueprint Medicines' strong financial performance, focus on sustainable growth, and strategic expansion into new therapeutic areas position the company for long-term success. Addressing challenges in physician adoption and patient prescription rates while leveraging growth opportunities in strategic partnerships and compound expansion will be crucial for future growth.

Blueprint Medicines excels in Q3 with robust AYVAKIT sales

Blueprint Medicines delivered strong revenue growth driven by AYVAKIT sales, showcasing high compliance and demand. With a focus on long-term growth and financial stability, the company aims to expand its impact with BLU-808 and maintain strong capital allocation priorities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

-- AYVAKIT® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. launch and recent EU approval -- -- Expanding mast cell disease leadership with oral wild-type KIT inhibitor, BLU-808, advancing into clinical development; IND submission planned in Q2 2024 -- -- Maintaining durable cash position through focused investment and global commercial execution -- -- Kate Haviland, Chief Executive Officer, to present at J.P. Morgan conference today at 10:30 a.m.

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference

Amgen

AstraZeneca

BioMarin Pharmaceutical

Bristol-Myers

Karuna Therapeutics Inc

Pfizer

Roche Holding AG

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

Alnylam Pharmaceuticals

argenx

Exelixis

Genmab - ADR

Incyte

Seagen

Sarepta Therapeutics

Alexion Pharma

Celgene

Horizon Pharma

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

5 Biotech Acquisition Targets To Accumulate In 2024

CAMBRIDGE, Mass. , Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42nd Annual J.P.

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.

Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up

-- In the European Union, patients with indolent systemic mastocytosis now have an approved medicine that treats the primary driver of disease  -- -- Approval based on data from PIONEER trial, in which AYVAKYT achieved significant improvements across a broad range of symptoms with a safety profile comparable to placebo 1   -- CAMBRIDGE, Mass. , Dec. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM franchise leadership --  CAMBRIDGE, Mass. , Dec. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12 in San Diego.

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting

CAMBRIDGE, Mass. , Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m.

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit

-- For the first time, the estimated 40,000 patients with indolent SM in the EU 1,2* would have a medicine that treats the primary disease driver 3,4  -- -- Opinion based on the positive PIONEER trial, in which once-daily AYVAKYT achieved significant improvements across a broad range of symptoms with a comparable safety profile to placebo 3,4 -- CAMBRIDGE, Mass. , Nov. 10, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis

The average of price targets set by Wall Street analysts indicates a potential upside of 42.2% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Blueprint Medicines (BPMC)? Wall Street Analysts Think 42.16%

Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.

Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat

Blueprint Medicines delivered an exceptional quarter with a positive reception for Ayvakit in its first full-quarter post-launch. More than 800 patients were using the ISM treatment at the end of Q3.

Why Blueprint Medicines Stock Soared Today

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Becker Hewes - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Eun Yang - Jefferies Brad Canino - Stifel Reni Benjamin - JMP Securities Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Derek Archila - Wells Fargo Ami Fadia - Needham Mike Ulz - Morgan Stanley Peter Lawson - Barclays David Lebowitz - Citi Chris Raymond - Piper Sandler Matt Biegler - Oppenheimer Operator Good morning. My name is Elliot and I will be your conference operator today.

Blueprint Medicines Corporation (BPMC) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Blueprint Medicines (BPMC) Q3 Earnings: A Look at Key Metrics

-- Achieved $54.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues, representing 90% growth year-over-year, and $56.6 million in total revenues in the third quarter of 2023 – -- Approximately 800 patients on AYVAKIT in the U.S. at the end of the third quarter, more than 35% growth in treated patients quarter-over-quarter and driven by ISM -- -- Plan to present data from Part 1 of the HARBOR trial of elenestinib in ISM at ASH 2023 – CAMBRIDGE, Mass., Oct. 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the third quarter ended September 30, 2023.

Blueprint Medicines Reports Third Quarter 2023 Results

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Blueprint Medicines (BPMC) Q3 Earnings Expected to Decline

CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?

On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicines' revenue for the second quarter of 2023 was $57.6 million, down 9% from the previous quarter and up 57.8% from the second quarter of 2022. The company's revenue growth was driven primarily by sales of Ayvakit, a tyrosine kinase inhibitor approved for treatment in a number of rare diseases in the US and Europe.

Blueprint Medicines: At The Forefront Of Groundbreaking Cancer Treatments

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.

Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates

Blueprint Medicines announced increased revenue and decreased losses. The company's lead therapy, Ayvakit, is now approved for three indications.

Why Shares of Blueprint Medicines Are Falling Wednesday

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Jenna Cohen - VP, IR Kate Haviland - CEO Philina Lee - CCO Fouad Namouni - President, R&D Mike Landsittel - CFO Christy Rossi - COO Becker Hewes - CMO Conference Call Participants Brad Canino - Stifel Dane Leone - Raymond James Reni Benjamin - JMP Securities Eun Yang - Jefferies Marc Frahm - TD Cowen Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Partners Ami Fadia - Needham Mike Ulz - Morgan Stanley Matt Biegler - Oppenheimer Peter Lawson - Barclays Derek Archila - Wells Fargo David Lebowitz - Citi Joel Beatty - Baird Operator Good morning, ladies and gentlemen. My name is Glen.

Blueprint Medicines Corporation (BPMC) Q2 2023 Earnings Call Transcript

Although the revenue and EPS for Blueprint Medicines (BPMC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Blueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

-- Achieved $39.9 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $57.6 million in total revenues in the second quarter of 2023 -- -- AYVAKIT approved by the FDA for the treatment of adults with indolent systemic mastocytosis on May 22, 2023 -- -- Announced development candidate BLU-808, an oral, highly potent and selective wild-type KIT inhibitor with first- and best-in-class potential, for the treatment of patients with mast cell disorders, including chronic urticaria – CAMBRIDGE, Mass. , Aug. 2, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2023.

Blueprint Medicines Reports Second Quarter 2023 Results

CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

News for Blueprint Medicines Stock (BPMC)